#Timi risk score for acs full
#Timi risk score for acs trial

Of the nine components of the TRS 2°P, hypertension (96.0%) and diabetes mellitus (40.3%) were the most commonly found in the DYSIS II population ( Table Table1 1).

#Timi risk score for acs full

For risk stratification using the TRS 2°P, a full data set was available for 5371 patients. Patients who were ≥18 years old were enrolled if they were attending an outpatient physician appointment for stable CHD between 20, and had a full lipid profile available from within the previous 12 months. All patients provided written informed consent. 5 The study complies with the Declaration of Helsinki and the research protocol was approved by ethics committees according to local regulations. The DYSIS II CHD study was a cross-sectional observational study of 6794 patients with stable coronary heart disease (CHD) in 18 countries across the globe. In addition, we evaluated the use of high intensity lipid-lowering therapy and achieved LDL-C in these high-risk groups to assess whether patterns of treatment were associated with patient risk. We therefore wished to assess the distribution of risk in a real-world population of patients with ASCVD as defined by the TRS 2°P. In addition, if broad application of preventive strategies such as ezetimibe are not possible due to resource constraints, identifying subgroups of post-ACS patients who are at even higher risk and therefore derive greater benefit from secondary preventative therapies may be useful. While RCT data are the foundation of clinical evidence when determining the therapeutic efficacy of drugs, patients are inherently highly selected and may represent the younger, healthier individuals among the disease population. Application of the TRS 2°P in IMPROVE-IT identified post-ACS patients at the highest risk for recurrent cardiovascular events who also derived the greatest absolute risk reduction with ezetimibe.ĬABG, coronary artery bypass graft eGFR, estimated glomerular filtration rate. 4 Overall, the addition of ezetimibe to simvastatin resulted in an achieved LDL-cholesterol (LDL-C) of 53.2 mg/dL compared with 69.9 mg/dL with simvastatin alone and, importantly, lower rates of cardiovascular events. 2 The TRS 2°P was recently applied in the IMPROVE-IT RCT, 3 where patients stabilized post-ACS were randomized to treatment with the cholesterol-lowering agent ezetimibe, or matching placebo, on a background of statin therapy.

#Timi risk score for acs trial

2 Developed with the use of data from a large randomized controlled trial (RCT), TRA 2°P-TIMI-50, 2 the TRS 2°P score is calculated based on the presence of nine risk factors, with each contributing a point ( Table Table1 1). In this context, the recently derived and validated TIMI Risk Score for Secondary Prevention (TRS 2°P) is a novel tool for better determiniation of an individual patient’s risk for major adverse cardiovascular events (MACE) after ACS. 1 Patients who suffer an acute coronary syndrome (ACS) are at further increased risk relative to those with stable disease and no history of ACS. Patients suffering from atherosclerotic cardiovascular disease (ASCVD) are at heightened risk for future atherothrombotic events, which are a leading cause of mortality worldwide.